E-newsletter CME Information

Release Date: December 2006

Valid Until: December 31, 2007

Introduction

Mounting evidence indicates that hyperglycemia in the hospital setting is associated with increased patient morbidity and mortality. Hyperglycemia is often the result of poorly controlled diabetes. Because the number of hospital patients with diabetes is increasing, the prevalence of inpatient hyperglycemia is also expected to rise. The occurrence of inpatient hyperglycemia is also increased by the number of patients without diabetes who experience hyperglycemia as result of illness and stress. Hyperglycemia activates mechanisms that can potentially contribute to morbidity and mortality, and it is increasingly clear that control of hyperglycemia in the inpatient setting through the use of insulin therapy can improve health outcomes, regardless of patients' diabetes status. The recognition that glycemic control is important to health outcomes in hospital settings has spurred the development of guidelines for the management of inpatient hyperglycemia. This activity provides an overview of the inpatient hyperglycemia issue and specifics regarding hyperglycemia on intensive care units and general medical/surgical floors. Topics addressed include the definition of hyperglycemia, the scope of the inpatient hyperglycemia problem, mechanisms by which hyperglycemia affects inpatient health outcomes, and current guidelines and strategies for the treatment of hyperglycemia.

Intended Audience

Primary care physicians and other healthcare professionals (HCPs) who treat patients with diabetes.

Method of Participation

This e-newsletter is an online summary of a symposium held in conjunction with the American Diabetes Association 66th Scientific Sessions in Washington, DC, on Saturday, June 10, 2006.

The participant should: 1) view the content and 2) complete and submit the CME demographic and evaluation form for credit. This activity should take approximately 60 minutes to complete. The expiration date for this activity is December 31, 2007. No credit will be granted after this date.

CME certificates will be issued to participants approximately 3 to 4 weeks after receipt of the CME demographic and evaluation form.

 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify the multiple mechanisms by which hyperglycemia can lead to increased morbidity and mortality in the inpatient setting

  • Describe the appropriate clinical application of insulin therapy for patients with diabetes in a critical care or cardiac care inpatient setting

  • Describe the appropriate clinical application of insulin therapy for patients with diabetes in a general medical or general surgical inpatient setting

 

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Center for Accredited Healthcare Education (CAHE) and International Medical Press (IMP). CAHE is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation Statements

CAHE designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Disclosures

In compliance with the ACCME, it is the policy of CAHE and IMP to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. CAHE also requires that faculty identify and reference off-label product or investigational use of pharmaceutical and medical device products.

In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and the Center for Accredited Healthcare Education policy, identification and resolution of conflict of interest has been made in the form of external peer review of educational content. The following disclosures have been made:

 

FACULTY

Claresa S Levetan, MD, FACE
Dr Levetan has no relevant financial relationships with any commercial interests.


Silvio E Inzucchi, MD
Specific Research Activities: Eli Lilly and Company


Guillermo E Umpierrez, MD, FACP, FACE
Formal Advisor: Amylin, Eli Lilly and Company, sanofi-aventis
Specific Research Activities: Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk, sanofi-aventis
Speaker’s Bureau: Amylin, Eli Lilly and Company, GlaxoSmithKline, sanofi-aventis, Takeda
Honoraria: Eli Lilly and Company, GlaxoSmithKline, sanofi-aventis, Takeda

 

CME Provider and Educational Partner Staff

All staff of CAHE and IMP in a position to influence content have filed statements of disclosure with the CME provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. These disclosures are available for review by contacting Steve Weinman at 1 609 936 7015 or e-mail at steve.weinman@cahe.com.

CAHE and IMP staffs have disclosed no conflicts of interest with the following exception:

 

Kimberly McFarland, PhD, Medical Writer

Spouse: Employed by GlaxoSmithKline

 

Disclaimer

This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

 

While the CAHE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

 

Commercial Support Acknowledgement

This activity is supported by an educational grant from Eli Lilly and Company.